Unmasking Potential Withdrawal Effects of Ashwagandha: A Case Report and Review.
Study Design
- Tipo di studio
- Case Report
- Dimensione del campione
- 1
- Intervento
- Unmasking Potential Withdrawal Effects of Ashwagandha: A Case Report and Review. Ashwagandha extract 600 mg/day (prior to discontinuation)
- Comparatore
- Placebo
- Direzione dell'effetto
- Negative
- Rischio di bias
- High
Abstract
Ashwagandha (Withania somnifera) is a widely available herbal product often taken for stress-related concerns. While it is typically well-tolerated, individuals may occasionally experience side effects. Symptoms emerging after the discontinuation of ashwagandha have not been extensively documented. We report the case of a 20-year-old male who presented with tachycardia, insomnia, and symptoms of anxiety following abrupt discontinuation of ashwagandha extract (600 mg/day). His medical workup, including cardiac enzymes, electrocardiogram, complete blood count, liver function tests, and thyroid function tests, was unremarkable. His symptoms began shortly after cessation of ashwagandha, and no other clear medical or psychosocial stressors were identified. He was treated supportively with hydroxyzine for sleep and referred for outpatient psychiatric follow-up. This case may represent a withdrawal syndrome related to ashwagandha cessation, potentially mediated by its GABA-ergic activity. Although alternative explanations, such as recurrence of underlying anxiety, are possible, the timing and severity of symptoms after discontinuation suggest a withdrawal phenomenon. This case highlights the importance of assessing herbal supplement use in patients presenting with new-onset psychiatric or autonomic symptoms. Clinicians should be aware of the potential for withdrawal symptoms following ashwagandha cessation. A thorough history of supplement use should be included in the evaluation of patients presenting with anxiety, insomnia, or related complaints.
Full Text
Figures
Figure 1
Timeline of symptom onset following ashwagandha (Withania somnifera) discontinuation in the case report documenting potential withdrawal effects.
diagram
Figure 2
Clinical course and symptom resolution following the reported ashwagandha withdrawal event, including any interventions and outcomes.
chartTables
Table 1
| Test name | Encounter result | Reference range and units |
| Hemoglobin | 16.4 | 13.2-16.6 g/dL |
| Hematocrit | 49.2 (H) | 38.3-48.6 % |
| Erythrocytes | 5.82 (H) | 4.35-5.65 x10¹²/L |
| MCV | 84.5 | 78.2-97.9 fL |
| RBC distribution width | 12.5 | 11.8-14.5 % |
| Platelet count | 296 | 135-317 x10⁹/L |
| Leukocytes | 7.5 | 3.4-9.6 x10⁹/L |
| Neutrophils | 5.23 | 1.56-6.45 x10⁹/L |
| Lymphocytes | 1.59 | 0.95-3.07 x10⁹/L |
| Monocytes | 0.52 | 0.26-0.81 x10⁹/L |
| Eosinophils | 0.09 | 0.03-0.48 x10⁹/L |
| Basophils | 0.03 | 0.01-0.08 x10⁹/L |
| D-dimer, P | 319 | ≤500 ng/mL FEU |
| Sodium, S | 138 | 135-145 mmol/L |
| Potassium, S | 4.7 | 3.6-5.2 mmol/L |
| Chloride, S | 102 | 98-107 mmol/L |
| Bicarbonate, S | 24 | 22-29 mmol/L |
| Anion gap | 12 | 7-15 |
| BUN (blood urea nitrogen), S | 19.2 | 8.0-24.0 mg/dL |
| Creatinine | 0.92 | 0.74-1.35 mg/dL |
| Estimated GFR (eGFR) | >90 | ≥60 mL/min/BSA |
| Calcium, total, S | 9.8 | 8.6-10.0 mg/dL |
| Glucose, S | 91 | 70-140 mg/dL |
| Bilirubin, total, S | 0.5 | 0.0-1.2 mg/dL |
| Alanine aminotransferase (ALT), S | 22 | 7-55 U/L |
| Aspartate aminotransferase (AST), S | 27 | 8-48 U/L |
| Alkaline phosphatase, S | 93 | 40-129 U/L |
| Protein, total, S | 7.6 | 6.3-7.9 g/dL |
| Albumin, S | 4.8 | 3.5-5.0 g/dL |
| Troponin T, baseline, 5th gen | 6 | ≤15 ng/L |
| TSH, sensitive | 1.12 | 0.30-4.20 mIU/L |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Journal of the American Academy of Dermatology · 2017
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Free radical biology & medicine · 2013
Epidemiology of selenium and type 2 diabetes: can we make sense of it?
Clinical and experimental dermatology · 1989
Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study.
Ophthalmology · 2021
Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2.
Drugs & aging · 2018